Targeted therapy in renal cell carcinoma

Expert Opinion on Investigational Drugs

Volumn 14, Issue 10, 2005, Pages 1251-1258

  Favaro, Justin P ^a   George, Daniel J ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Bevacizumab; Epidermal growth factor; Epidermal growth factor receptor; Erlotinib; MTOR; Rapamycin; Renal cell carnicoma; Tyrosine kinase inhibitor; VEGF; VEGFR

Indexed keywords

BEVACIZUMAB; CETUXIMAB; CYTOPLASM PROTEIN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FIBRINOGEN; FLT3 LIGAND; GAMMA INTERFERON; GEFITINIB; IMATINIB; INTERLEUKIN 2; MITOGEN ACTIVATED PROTEIN KINASE; PANITUMUMAB; PLACEBO; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEASOME INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VATALANIB; VON HIPPEL LINDAU PROTEIN;

ACNE; ANEMIA; ANGIOGENESIS; ASTHENIA; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CARCINOGENESIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIARRHEA; DISEASE COURSE; DRUG DOSE REGIMEN; DRUG MECHANISM; DRUG RESPONSE; DRUG TARGETING; DRUG WITHDRAWAL; FATIGUE; GENE MUTATION; GENE TARGETING; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; KIDNEY CARCINOMA; MEDICAL RESEARCH; MUCOSA INFLAMMATION; NAUSEA; PANCREAS DISEASE; PREDICTION; PROTEINURIA; PRURITUS; RASH; REVIEW; STATISTICAL SIGNIFICANCE; STOMATITIS; THROMBOCYTOPENIA;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DRUG DELIVERY SYSTEMS; HUMANS; KIDNEY NEOPLASMS; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 27144489762     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.14.10.1251     Document Type: Review

References (43)

1. SOCIETY AC: Cancer facts and figures, American Cancer Society (2003):4.
2. DUTCHER JP: Interleukin-2 based therapy for kidney cancer. Cancer Treat. Res. (2003) 116:155-172.
3. COLLICHIO FAMDP, KISHAN MD: Interferon [α]-2b and megestrol acetate in the treatment of advanced renal cell carcinoma: a Phase II study. Am. J. Clin. Oncol. (1998) 21(2):209-211.
4. 2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J. Clin. Oncol. (1999) 17:2859-2867.
5. WAGNER J, LINEHAN WM: Molecular genetics of renal cell carcinoma. Semin. Urol. Oncol. (1996) 14(4):244-249.
6. GNARRA DD Jr, WENG Y, HUMPHREY JS et al.: Molecular cloning of the von Hippel-Lindau tumor suppressor gene and its role in renal cell carcinoma. Biochim. Biophys. Acta (1996) 1242(3):201-210.
7. KAELIN W. The von Hippel-Lindau tumor suppressor gene and kidney cancer. Clin. Cancer Res. (2004) 10(18 Part 2):6290S-6295S.
8. DATTA K, SUNDBERG C, KARUMANCHI SA, MUKHOPADHYAY D: The 104-123 amino acid sequence of the beta-domain of von Hippel-Lindau gene product is sufficient to inhibit renal tumor growth and invasion. Cancer Res. (2001) 61(5):1768-1775.
9. BARNES C, KUMAR R: Biology of the epidermal growth factor receptor family. Cancer Treat. Res. (2004) 119:1-13.
10. DAWSON N, GUO C, ZAK R et al.: A Phase II trial of ZD1839 in stage IV and recurrent renal cell carcinoma. Proc. Am. Soc. Clin. Oncol. (2003) 22:404 (Abstract 1623).
11. JERMANN MJM, PLESS M, SALZBERG M et al.: An open-label Phase II trial to evaluate the efficacy and safety of gefitinib in patients with locally advanced, relapsed or metastatic renal cell cancer. Proc. Am. Soc. Clin. Oncol. (2003) 22:418 (Abstract 1681).
12. ROWINSKY SG, GOLLOB JA, THOMPSON JA et al.: Safety pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J. Clin. Oncol. (2004) 22(15):3003-3015.
13. MOTZER RJ, TODD M, HWU WJ et al.: Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma. Invest. New Drugs (2003) 21(1):99-101.
14. FERRARA N, LECOUTER J: The biology of VEGF and its receptors. Nat. Med (2003) 9(6):669-676.
15. GERBER KJ, SHERMAN D, EBERHARD DA, FERRARA N: Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. Cancer Res. (2000) 60(22):6253-6258.
16. KIM KJ, WINER J, ARMANINI M, GILLETT N, PHILLIPS HS, FERRARA N: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature (1993) 362(6423):841-844.
17. PREWETT MHJ, LI Y, SANTIAGO A et al.: Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res. (1999) 59(20):5209-5218.
18. YANG JCHL, SHERRY RM, HWU P et al.: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. (2003) 349(5):427-434.
19. GEORGE DMD, OH WK, REITSMA D et al.: Phase I study of PTK-787/ZK-222584 (PTK/ZK) in metastatic renal cell carcinoma. Proc. Am. Soc. Clin. Oncol. (2003) 22:385 (Abstract 1548).
20. MORGAN BTA, DREVS J, HENNIG J et al.: Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK-787/ZK-222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two Phase I studies. J. Clin. Oncol. (2003) 21(21):3955-3964.
21. DE BAZELAIRE CDA, ROFSKY N, WANG Y et al.: MRI-assessed changes in tumor blood flow following treatment with PTK/ZK correlate with subsequent tumor shrinkage or growth in patients with metastatic renal cell carcinoma. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston, USA (2003).
22. DREVS M-DR, WITTIG C, FUXIUS S et al.: PTK-787/ZK-222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging. Cancer Res. (2002) 62(14):4015-4022.
23. VUKY J FM, ISACSON C, DELA CRUZ J et al.: Phase II trial of ematinib mesylate (formerly known as STI-571) in patients with metastatic renal cell carcinoma (RCC). Proc. Am. Soc. Clin. Oncol. (2003) 22:416.
24. HAINSWORTH SJ, SPIGEL DR, SCHWERT RC, CARRELL DL, HUBBARD F, GRECO FA: Phase II trial of bevacizumab and erlotinib in patients with metastatic renal carcinoma (RCC). Journal of Clinical Oncology ASCO Annual Meeting Proceedings (Post-Meeting Edition) (2004) 22(14S):4502.
25. SPIGEL DR, SOSMAN JA, RAEFSKY EL et al.: Bevacizumab and erlotinib in the treatment of patients with metastatic renal carcinoma (RCC): update of a Phase II multicenter trial. 2005 ASCO Annual Meeting, Orlando, USA (2005).
26. HAINSWORTH JD, SPIGEL DR, PATTON JF et al.: Bevacizumab, erlotinib, and imatinib in the treatment of patients (pts) with advanced renal cell carcinoma (RCC): a Minnie Pearl Cancer Research Network Phase I/II trial. 2005 ASCO Annual Meeting, Orlando, USA (2005).
27. SCHWARTZ L, WANG MM, SMITH LA, MARION S, PANICEK D, MOTZER R: Effect of response criteria on outcome assessment for patients with advanced renal cell carcinoma. Proc. Am. Soc. Clin. Oncol. (2003) 22:385.
28. MOTZER RJ BIR, MICHAELSON MD, REDMAN RG et al.: The SU11248 Study Group: Phase II trials of SU11248 show antitumour activity in second-line therapy for patients with renal cell carcinoma (RCC) 2005 ASCO Annual Meeting, Orlando, USA (2005):FL2005.
29. RINI BOR, BUKOWSKI R, MICHAELSON MD et al.: AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a Phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC). 2005 ASCO Annual Meeting, Orlando, USA (2005).
30. ESCUDIER BCS, EISEN T, STADLER WM, SCHWARTZ B, SHAN M, BUKOWSKI RM: Randomized Phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY-43-9006) in patients with advanced renal cell carcinoma (RCC). 2005 ASCO Annual Meeting, Orlando, USA (2005).
31. OKA H CY, HOSHINO R, OGAWA O et al.: Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma. Cancer Res. (1995) 55(18):4182-4187.
32. CHONG HVH, GUAN KL: Mechanisms of regulating the Raf kinase family. Cell Signal. (2003) 15(5):463-469.
33. HAY SN: Upstream and downstream of mTOR. Genes Dev. (2004) 18(16):1926-1945.
34. ATKINS MB, STADLER WM, LOGAN TF et al.: Randomized Phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J. Clin. Oncol. (2004) 22(5):909-918.
35. HIDALGO M: New target, new drug, old paradigm. J. Clin. Oncol. (2004) 22(12):2270-2272.
36. HUANG SBM, HOUGHTON PJ: Rapamycins: mechanism of action and cellular resistance. Cancer Biol. Ther. (2003) 2(3):222-232.
37. SHAW VARB, PARK JW, SMALL EJ: A Phase 2 study of UCN-01 in advanced renal cell carcinoma. Proc. Am. Soc. Clin. Oncol. (2003) 22:442.
38. DAVIS NB, ANSARI RH, RYAN CW, VOKES EE, VOGELZANG NJ, STADLER WM: A Phase II trial of PS-341 in patients (pts) with renal cell cancer (RCC). Proc. Am. Soc. Clin. Oncol. (2003) 22:386.
39. DRUCKER BJ, BACIK J, MAZUMDAR M, MARION S, MOTZER RJ: Phase II trial of PS-341 shows response in patients with advanced renal cell carcinoma. Proc. Am. Soc. Clin. Oncol. (2003) 22:386.
40. COBB PW, VENNER P, VOEGELE J, MOSCOVICI M, MARKOVITZ E, COPPIETERS S: An uncontrolled Phase II multi-center trial evaluating anti-tumor efficacy and safety of BAY-59-8862 in patients with advanced renal cell cancer. Proc. Am. Soc. Clin. Oncol. (2003) 22:408.
41. THOMPSON JA, ESCUDIER B, DUTCHER JP et al.: Phase II trial evaluating the safety and efficacy of EPO906 in patients with advanced renal cancer. Proc. Am. Soc. Clin. Oncol. (2003) 22:405.
42. ZHUANG SH, KOTZ H, AGRAWAL M et al.: A Phase II clinical trial of BMS-247550 (ixabepilone), a microtubule-stabilizing agent in renal cell cancer. Journal of Clinical Oncology ASCO Annual Meeting Proceedings, New Orleans, USA (2004).
43. MacKLER NJ MB, REDMAN B, RHODES D, CHINNAIYAN A: The PI3K/AKT pathway in renal (clear cell) carcinoma via meta-analysis of expression microarrays. 2005 ASCO Annual Meeting, Orlando, USA (2005).